- Zacks•3 days ago
Puma (PBYI) announced that its Marketing Authorization Application for neratinib has been validated by the European Medicines Agency.
- Barrons.com•4 days ago
Now that Medivation (MDVN) has agreed to be bought by Pfizer (PFE), Citigroup's Yigal Nochomovitz and Yang Huang argue that Ophthotech (OPHT), Puma Biotechnology (PBYI), Lexicon Pharmaceuticals (LXRX), ...
- Business Wire•4 days agoPuma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the Marketing Authorization Application for neratinib has been validated by the European Medicines Agency .
Puma Biotechnology, Inc. (PBYI)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||56.56 x 1000|
|Ask||57.49 x 1600|
|Day's Range||56.81 - 58.35|
|52wk Range||19.74 - 107.49|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-7.23|
|Avg Vol (3m)||708,842|
|Dividend & Yield||N/A (N/A)|